Skip to Main Content

Hyunseok (Hyu) Kang


Medical oncologist
Specialized cancer researcher and classical music lover

About me

Pronouns: He | Him | His

Dr. Hyunseok Kang, who goes by Hyu, is a specialist in cancer treatment who cares for adults with head and neck cancers. His expertise encompasses conventional chemotherapy, targeted therapy (which selectively goes after cancer cells) and immunotherapy (which stimulates the patient's own immune system to fight the cancer).

In his research, Kang focuses on evaluating new therapies for head and neck cancers through clinical trials. He studies how to improve the efficacy of immune checkpoint inhibitors (drugs that turn off the ability of some cancer cells to evade detection by immune system cells) with combination approaches to treating head and neck squamous cell carcinomas. He is also working on developing targeted approaches to treat rare cancers of the head and neck, such as salivary gland cancers.

Kang earned his medical degree at Yonsei University College of Medicine in Seoul, South Korea. He went on to earn a master's degree in public health, epidemiology and statistics from Yonsei University Graduate School of Public Health. He completed his residency in internal medicine at Mount Sinai St. Luke's and Mount Sinai West, followed by a fellowship in hematology and medical oncology at Emory University School of Medicine.

Kang is a fellow of the American College of Physicians. He is a member of the American Society of Clinical Oncology, American Association for Cancer Research, Society for Immunotherapy of Cancer and American Thyroid Association. He also serves on specialty head and neck committees for NRG Oncology and the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network.

Prior to joining UCSF, Kang worked as a medical oncologist at the Johns Hopkins Hospital and served as an assistant professor of oncology at the Johns Hopkins University School of Medicine.

To reach Dr. Hyunseok Kang, please contact the head and neck medical oncology practice at (415) 353-9900.

  • Education

    Yonsei University Graduate School of Public Health, MPH, 2007

    Yonsei University College of Medicine, MD, 2002

  • Residencies

    Mount Sinai St. Luke's and Mount Sinai West, Internal Medicine, 2010

  • Fellowships

    Emory University School of Medicine, Hematology and Medical Oncology, 2013

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages


Where I see patients (1)

    My reviews


    Overall Experience
    121 Ratings
    Explained things in a way that was easy to understand
    121 Ratings
    Did the doctor pay attention to your concerns
    121 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    118 Ratings
    Knew the important information about your medical history
    119 Ratings
    The provider showed respect for what you had to say
    120 Ratings
    The provider spent enough time with me
    120 Ratings
    I believe we can improve outcomes for cancer patients with personalized approaches based on research into precision therapies.
    Decorative Caduceus

    RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Adv...

    Evaluate the safety and tolerability of RM-1995 photoimmunotherapy treatment, and determine the MTD or MAD


    Decorative Caduceus

    A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Posi...

    Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment


    Decorative Caduceus

    Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Me...

    RECIST 1.1


    Decorative Caduceus

    NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surger...

    The proportion of patients experiencing grade 3 or 4 adverse events assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be reported with exact binomial 95% confidence intervals. Sa...